Home > Insider Trading > Filing (0001179110-18-012637)

Filing Details

Accession Number:: 0001179110-18-012637
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-11-07 16:25:22
Reporting Period:: 2018-11-05

Accepted Time:: 2018-11-07 16:25:22
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1597264	Blueprint Medicines Corp	BPMC	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1638474	W. Jeffrey Albers	C/O Blueprint Medicines Corporation 45 Sidney Street Cambridge MA 02139	Ceo And President	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-11-05	20,000	$1.87	20,000	No	4	M	Direct
Common Stock	Disposition	2018-11-05	1,100	$65.53	18,900	No	4	S	Direct
Common Stock	Disposition	2018-11-05	1,500	$64.18	17,400	No	4	S	Direct
Common Stock	Disposition	2018-11-05	17,300	$63.30	100	No	4	S	Direct
Common Stock	Disposition	2018-11-05	100	$62.66	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2018-11-05	20,000	$0.00	20,000	$1.87

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
915,034		2024-07-30	No	4	M	Direct

Footnotes

The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 20, 2017 pursuant to Rule 10b5-1 under the Exchange Act.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.04 to $66.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (6) to this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.84 to $64.81 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.77 to $63.76 per share.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.65 to $62.66 per share.
This option was granted on July 30, 2014. This option vests as follows: (i) 42,845 shares vested in four installments at a rate of 6,974 shares on September 21, 2016, and 11,957 shares on each of October 21, 2016 and November 21, 2016, and 11,957 on December 21, 2016; (ii) 90,010 shares vested in eight installments at a rate of 6,311 shares on May 21, 2017 and 11,957 shares on each of June 21, 2017, July 21, 2017, August 21, 2017, September 21, 2017, October 21, 2017, November 21, 2017 and December 21, 2017; and (iii) 30,225 shares vest in three installments at a rate of 6,311 shares on May 21, 2018, 11,957 shares on June 21, 2018 and 11,957 shares on July 21, 2018.